Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080384 | 0.84 | KDM4E (0.46) | P2RX3ALDH1A1MAPTSMN1; SMN2PDE10A | |
| SCHEMBL6080337 | 0.82 | CDK9 (0.41) | P2RX3ALDH1A1MAPTSMN1; SMN2DYRK1A | |
| SCHEMBL6080402 | 0.82 | PARP1 (0.44) | P2RX3ALDH1A1MAPTSMN1; SMN2PDE10A | |
| SCHEMBL6080782 | 0.79 | DHODH (0.50) | ALDH1A1MAPTSMN1; SMN2PDE10ADHODH | |
| SCHEMBL6080196 | 0.79 | CNR2 (0.37) | P2RX3ALDH1A1MAPTSMN1; SMN2PDE10A | |
| SCHEMBL6080920 | 0.79 | PDE10A (0.50) | ADORA2AALDH1A1MAPTSMN1; SMN2DYRK1A | |
| SCHEMBL2123640 | 0.79 | PARP1 (0.36) | AURKAADORA2AADORA1GRM2PDE10A | |
| SCHEMBL28852217 | 0.79 | PARP1 (0.36) | AURKAADORA2AADORA1P2RX3GRM2 | |
| SCHEMBL6080122 | 0.78 | SLC22A12 (0.37) | ADORA2AADORA1P2RX3GRM2ALDH1A1 | |
| SCHEMBL1123893 | 0.78 | ALB (0.46) | AURKAALBADORA2AADORA1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1000060-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002528-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | AURKA 1426/4885ALB 2810/4885ADORA2A 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.